Adrenocortical tumours: challenges and recent advances in diagnosis and treatment

Ronchi, Cristina

DOI:

[10.23736/S0391-1977.18.02915-2](https://doi.org/10.23736/S0391-1977.18.02915-2)

License:

None: All rights reserved

Document Version

Peer reviewed version

Citation for published version (Harvard):

Ronchi, C 2018, 'Adrenocortical tumours: challenges and recent advances in diagnosis and treatment', *Minerva endocrinologica*. <https://doi.org/10.23736/S0391-1977.18.02915-2>

[Link to publication on Research at Birmingham portal](#)

Publisher Rights Statement:

Checked for eligibility: 28/09/2018

First published in:

Minerva Endocrinologica 2018 Sep 12

DOI: 10.23736/S0391-1977.18.02915-2

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

Special Issue of the Journal *Minerva Endocrinologica*

“Unilateral non-aldosterone producing adrenocortical tumors”

Title: Adrenocortical tumours: challenges and recent advances in diagnosis and treatment

Editorial

^{1,2,3}Cristina L. Ronchi

¹Institute of Metabolism and System Research, University of Birmingham, United Kingdom; ²Centre for Endocrinology, Diabetes and Metabolism (CEDAM), Birmingham Health Partners; ³Division of Endocrinology and Metabolism, University Hospital of Wuerzburg, Wuerzburg, Germany.

Unilateral adrenocortical tumors consist in frequent benign adrenocortical adenomas (ACA) and rare malignant adrenocortical carcinomas (ACC). On one side, ACAs are among the most common human neoplasia with a reported prevalence of 2-10% in the general population. They are generally endocrine inactive and clinically unapparent, thus being often incidentally-discovered. However, in 30% of cases ACAs may be associated with autonomous steroid (cortisol or aldosterone) secretion and clinical syndromes that may induce severe morbidities and even increase mortality (1, 2). On the other side, ACC are extremely rare cancers with a usually aggressive clinical outcome (mean 5-year survival rate 20-50%), mostly depending on initial tumour stage (3) and other clinical or histopathological parameters, such as the ki67 proliferation index (4, 5). For this reason it is important to precociously differentiate ACC from ACAs. Nowadays, the differential diagnosis mostly relies on a series of histopathological malignant criteria included in the Weiss score. Nevertheless, some cases still remain undefined (6), so that we are still looking for reliable diagnostic markers that may allow to precisely differentiate benign from malignant adrenocortical tumours. For instance, new techniques have been proposed, such as the urine steroid metabolome analysis (7), but their role in a routine setting needs to be validated.

In recent years, thanks to collaborative efforts and technological advances, different research groups performed pan-genomic studies that allowed a significant improvement in knowledge of

pathogenic mechanisms involved in adrenal tumour development and progression as well as in steroid autonomous secretion (8-11). For instance, in the field of ACA, somatic *PRKACA* mutations have been only recently reported to be involved in the pathogenesis of 35-65% of cortisol-producing adenomas (CPA) associated with overt Cushing syndrome (12). Thanks to this finding, we are now aware that the pathogenesis of up to 60% of CPA is due to genetic alterations in the cAMP/PKA pathway (i.e. affecting *PRKACA* and *GNAS* genes). Moreover, somatic mutations in *KCNJ5* (K⁺ channel), *ATP1A1* (Na⁺K⁺-ATPase), *ATP2B3* (Ca²⁺-ATPase) and *CANCAID* (Ca²⁺ channel, L type), have been recently found to be associated with the pathogenesis of 40-70% of aldosterone-producing adenomas (APA) (13).

Despite these important improvements in terms of molecular pathogenesis, many clinically-relevant questions on ACA still remain unanswered. For instance: How can we accurately diagnose the presence of a clinically unapparent (“subclinical” or mild) cortisol excess (Cushing syndrome) in patients affected by CPA? Which are the clinical implications and consequences of the presence of autonomous cortisol secretion in absence of overt clinical symptoms? Which are the best strategies for the management of patients with incidentally discovered endocrine inactive adenomas or with “subclinical” CPA?

Considering the ACC, novel genetic alterations have been discovered to be involved in their pathogenesis (e.g. in genes *ZNRF3*, *DAXX*, *TERT*, *MED12*, *PRKARIA*, *RPL22*, *TERF2*, *CCNE1*, and *NFI*) and/or associated with more aggressive behaviour and worst prognosis (8, 9). However, fully reliable and easy-applicable clinical and molecular prognostic factors for patients with ACC are still missing. In addition, up to date, only few pharmacological treatments are available for patients with advanced ACC. Some previous studies aimed to identify potential drug targets that might be useful for innovative therapeutic approaches in patients with advanced ACC, unfortunately without satisfying results (14, 15). On this connection, a very recent paper from our group demonstrated that targeted molecular profiling of tumor samples on formalin-fixed paraffin-embedded specimens is feasible and able to simultaneously improve prognostication of ACC beyond clinical/histopathological parameters and identify new potential drug targets (16). These findings might then pave the way to a precision medicine approach to ACC.

To summarise, basic and translational research on adrenocortical tumors is an active field that generated very promising advances during the last few years. Prominent examples include an improved understanding of adrenal tumor molecular pathogenesis as well as the introduction of new potential diagnostic and prognostic biomarkers. International collaboration as well as the use of innovative technology will be key factors to accelerate improvements in our knowledge of pathogenic mechanisms and in our skills for better diagnosis, prognosis and treatment of patients with these tumors. This will be possible only through joint efforts especially both within the European (European Network for the Study of Adrenocortical Tumours ENSAT, <http://www.ensat.org/>) and the extra-European community ([The American-Australian-Asian Adrenal Alliance A5,
https://elselab.wordpress.com/a5/](http://www.a5alliance.org/)). However, at the moment, routine management strategy for adrenocortical tumours might be challenging in several steps and should be decided in the setting of a multidisciplinary team in expert centers.

In this special issue, we present a number of systemic reviews focusing on the state-of-the-art about pathogenesis, diagnosis, prognosis and treatment of unilateral adrenocortical tumours focusing on non-aldosterone-producing ones. The Authors also give specific insights into future approaches proposed to improve the management of patients with adrenocortical tumours.

References

1. Fassnacht M, Arlt W, Bancos I, Dralle H, Newell-Price J, Sahdev A, Tabarin A, Terzolo M, Tsagarakis S, Dekkers OM. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. *Eur J Endocrinol.* 2016 175 G1-G34.
2. Crona J, Beuschlein F, Pacak K, Skogseid B. Advances in adrenal tumors 2018. *Endocr Relat Cancer.* 2018 25 R405-R420.
3. Fassnacht M, Johanssen S, Quinkler M, Bucszy P, Willenberg HS, Beuschlein F, Terzolo M, Mueller HH, Hahner S, Allolio B; German Adrenocortical Carcinoma Registry Group; European Network for the Study of Adrenal Tumors. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification. *Cancer* 2009 115 243-250
4. Beuschlein F, Weigel J, Saeger W, Kroiss M, Wild V, Daffara F, Libé R, Ardito A, Al Ghuzlan A, Quinkler M, Oßwald A, Ronchi CL, de Krijger R, Feelders RA, Waldmann J, Willenberg HS, Deutschbein T, Stell A, Reincke M, Papotti M, Baudin E, Tissier F, Haak HR, Loli P, Terzolo M,

Allolio B, Müller HH, Fassnacht M. Major prognostic role of Ki67 in localized adrenocortical carcinoma after complete resection. *J Clin Endocrinol Metab* 2015 100 841-849

5. Libé R, Borget I, Ronchi CL, Zaggia B, Kroiss M, Kerkhofs T, Bertherat J, Volante M, Quinkler M, Chabre O, Bala M, Tabarin A, Beuschlein F, Vezzosi D, Deutschbein T, Borson-Chazot F, Hermesen I, Stell A, Fottner C, Leboulleux S, Hahner S, Mannelli M, Berruti A, Haak H, Terzolo M, Fassnacht M, Baudin E; ENSAT network. Prognostic factors in stage III-IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study. *Ann Oncol*. 2015 26 2119-2125

6. Else T, Kim AC, Sabolch A, Raymond VM, Kandathil A, Caoili EM, Jolly S, Miller BS, Giordano TJ, Hammer GD. Adrenocortical carcinoma. *Endocr Rev*. 2014 35 282-326

7. Arlt W, Biehl M, Taylor AE, Hahner S, Libé R, Hughes BA, Schneider P, Smith DJ, Stiekema H, Krone N, Porfiri E, Opocher G, Bertherat J, Mantero F, Allolio B, Terzolo M, Nightingale P, Shackleton CH, Bertagna X, Fassnacht M, Stewart PM. Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors. *J Clin Endocrinol Metab*. 2011 96 3775-84

8. Ronchi CL, Sbiera S, Leich E, Henzel K, Rosenwald A, Allolio B, Fassnacht M. Single nucleotide polymorphism array profiling of adrenocortical tumors--evidence for an adenoma carcinoma sequence? *PLoS One*. 2013 8 e73959

9. Assié G, Letouzé E, Fassnacht M, Jouinot A, Luscip W, Barreau O, Omeiri H, Rodriguez S, Perlemoine K, René-Corail F, Elarouci N, Sbiera S, Kroiss M, Allolio B, Waldmann J, Quinkler M, Mannelli M, Mantero F, Papatthomas T, De Krijger R, Tabarin A, Kerlan V, Baudin E, Tissier F, Dousset B, Groussin L, Amar L, Clauser E, Bertagna X, Ragazzon B, Beuschlein F, Libé R, de Reyniès A, Bertherat J.. Integrated genomic characterization of adrenocortical carcinoma. *Nat Genet* 2014 46 607-612

10. Zheng S, Cherniack AD, Dewal N, Moffitt RA, Danilova L, Murray BA, Lerario AM, Else T, Knijnenburg TA, Ciriello G, Kim S, Assie G, Morozova O, Akbani R, Shih J, Hoadley KA, Choueiri TK, Waldmann J, Mete O, Robertson AG, Wu HT, Raphael BJ, Shao L, Meyerson M, Demeure MJ, Beuschlein F, Gill AJ, Sidhu SB, Almeida MQ, Fragoso MCBV, Cope LM, Kebebew E, Habra MA, Whitsett TG, Bussey KJ, Rainey WE, Asa SL, Bertherat J, Fassnacht M, Wheeler DA; Cancer Genome Atlas Research Network, Hammer GD, Giordano TJ, Verhaak RGW Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. *Cancer Cell* 2016 29 723-736

11. Ronchi CL, Di Dalmazi G, Faillot S, Sbiera S, Assié G, Weigand I, Calebiro D, Schwarzmayer T, Appenzeller S, Rubin B, Waldmann J, Scaroni C, Bartsch DK, Mantero F, Mannelli M, Kastelan D, Chiodini I, Bertherat J, Reincke M, Strom TM, Fassnacht M, Beuschlein F on behalf of ENSAT. Genetic landscape of sporadic unilateral adrenocortical adenomas without *PRKACA* p.Leu206Arg mutation. *J Clin Endocrinol Metab*. 2016 7 jc20161586

12. Calebiro D, Di Dalmazi G, Bathon K, Ronchi CL, Beuschlein F. cAMP signaling in cortisol-producing adrenal adenoma. *Eur J Endocrinol*. 2015 173 M99-106.

13. Fernandes-Rosa FL, Williams TA, Riester A, Steichen O, Beuschlein F, Boulkroun S, Strom TM, Monticone S, Amar L, Meatchi T, Mantero F, Cicala MV, Quinkler M, Fallo F, Allolio B, Bernini G, Maccario M, Giacchetti G, Jeunemaitre X, Mulatero P, Reincke M, Zennaro MC Genetic spectrum and clinical correlates of somatic mutations in aldosterone-producing adenoma. Hypertension. 2014 64 354-61

14. De Martino MC, Al Ghuzlan A, Aubert S, Assié G, Scoazec JY, Leboulleux S, Do Cao C, Libé R, Nozières C, Lombès M, Pattou F, Borson-Chazot F, Hescot S, Mazoyer C, Young J, Borget I, Colao A, Pivonello R, Soria JC, Bertherat J, Schlumberger M, Lacroix L, Baudin E. Molecular screening for a personalized treatment approach in advanced adrenocortical cancer. *J Clin Endocrinol Metab* 2013 98 4080-4088

15. Ronchi CL, Kroiss M, Sbiera S, Deutschbein T, Fassnacht M. EJE prize 2014: current and evolving treatment options in adrenocortical carcinoma: where do we stand and where do we want to go? *Eur J Endocrinol.* 2014 171 R1-R11
16. Lippert J, Appenzeller S, Liang R, Sbiera S, Kircher S, Altieri B, Nanda I, Weigand I, Gehrig A, Steinhauer S, Riemens RJM, Rosenwald A, Mueller C, Kroiss M, Rost S, Fassnacht M, Ronchi CL, Targeted molecular analysis in adrenocortical carcinomas: a strategy towards improved personalized prognostication. *J Clin Endocrinol Metab* 2018 in press